Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy (Zacks) +++ MINERVA NEUROSCIENCES Aktie +4,99%

PFIZER Aktie

 >PFIZER Aktienkurs 
22.19 EUR    +0.3%    (TradegateBSX)
Ask: 22.21 EUR / 5450 Stück
Bid: 22.185 EUR / 5450 Stück
Tagesumsatz: 75204 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
PFIZER Aktie über LYNX handeln
>PFIZER Performance
1 Woche: +0,3%
1 Monat: -5,7%
3 Monate: -3,2%
6 Monate: +2,0%
1 Jahr: +8,0%
laufendes Jahr: +3,9%
>PFIZER Aktie
Name:  PFIZER INC. DL-,05
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US7170811035 / 852009
Symbol/ Ticker:  PFE (Frankfurt) / PFE (NYSE)
Kürzel:  FRA:PFE, ETR:PFE, PFE:GR, NYSE:PFE
Index:  S&P500
Webseite:  https://www.pfizer.com/
Profil:  Pfizer Inc. is a leading biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells prescription drugs and vaccines worldwide. Operating in segments including Biopharma, PC1, and Pfizer Ignite, it focuses on key..
>Volltext..
Marktkapitalisierung:  124327.76 Mio. EUR
Unternehmenswert:  169237.83 Mio. EUR
Umsatz:  54526.43 Mio. EUR
EBITDA:  20437.83 Mio. EUR
Nettogewinn:  6428.81 Mio. EUR
Gewinn je Aktie:  1.13 EUR
Schulden:  55508.19 Mio. EUR
Liquide Mittel:  1466.61 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  0.38
Umsatzwachstum:  -5.09%
Gewinnwachstum:  -11.15%
Dividende je Aktie:  1.47 EUR
Dividendenrendite:  6.79%
Dividendenschätzung:  6.82%
Div. Historie:  08.05.26 - 0.364726€
23.01.26 - 0.363694€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  PFIZER
Letzte Datenerhebung:  20.05.26
>PFIZER Kennzahlen
Aktien/ Unternehmen:
Aktien: 5699.44 Mio. St.
Frei handelbar: 99.89%
Rückkaufquote: -
Mitarbeiter: 75000
Umsatz/Mitarb.: 0.72 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 12.85%
Bewertung:
KGV: 19.53
KGV lG: 8.68
KUV: 2.29
KBV: 1.61
PEG-Ratio: -
EV/EBITDA: 8.28
Rentabilität:
Bruttomarge: 65.16%
Gewinnmarge: 11.81%
Operative Marge: 27.08%
Managementeffizenz:
Gesamtkaprendite: 3.6%
Eigenkaprendite: 8.29%
 >PFIZER Anleihen 
>PFIZER Peer Group
 
20.05.26 - 18:16
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion (Zacks)
 
PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs....
20.05.26 - 13:21
Pfizer begins late-stage trial for new pneumococcal shot in infants after strong Phase 2 data (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.05.26 - 11:18
Pfizer Advances Pneumonia Shot After Getting Positive Results in Children (Bloomberg)
 
Pfizer Inc. said a new version of its bestselling Prevnar vaccine may provide infants with better protection against common strains of pneumonia than currently available immunizations....
15.05.26 - 17:31
Pfizer Aktie: Trotz Umsatzplus weiter begrenztes Potenzial! (Aktiencheck)
 
New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von Wolfe Research: Wolfe-Research-Analystin Alexandria Hammond habe das Kursziel für die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) leicht von 25 auf 26 USD angehoben, die Einstufung "underperform" jedoch bestätigt. [mehr]...
15.05.26 - 15:54
Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why (24/7 Wall St.)
 
Pfizer (NYSE:PFE) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at $41.29 trade at defensive, cash-generative valuations. Michael Burry purchased these shares for their real earnings and margin stability, and with inflation still pressuring margins across the market, names that generate cash, hold pricing power, and trade at sober multiples carry a structural ... Michael Burry's Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why...
14.05.26 - 17:24
Pfizer Just Locked In Its Next 5 Years of Growth -- Here′s How (Fool)
 
The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and money to work on other profit centers....
14.05.26 - 16:00
US Govt Settles With Former NYT Reporter In Biden/Twitter Censorship Case (ZeroHedge)
 
US Govt Settles With Former NYT Reporter In Biden/Twitter Censorship Case Authored by Zachary Stieber via The Epoch Times, The U.S. government has reached a settlement with a former New York Times reporter who was kicked off Twitter during the COVID-19 pandemic for posts about vaccines. Officials in a settlement agreement dated May 11 and obtained by The Epoch Times said that the government “did in fact violate the First Amendment by exerting substantial coercive pressure on social media companies such as Twitter to suppress disfavored speech like Plaintiff's,” referring to former New York reporter Alex Berenson. Officials said they were paying Berenson $150,000 to settle the case, which was filed in 2023 against then-President Joe Biden, Pfizer board member Dr. Scott Gottlieb, and others. In exchange, Berenson moved to dismiss the case. “I'd like to thank the Trump administration for acknowledging the government's unconstitutional actions against me in 2021 and standing for my First ...
14.05.26 - 13:00
The Zacks Analyst Blog Meta, Pfizer, Salesforce and Smith-Midland (Zacks)
 
Meta ramps AI infrastructure spending as upgraded recommendations and advertiser tools boost engagement and ad efficiency....
14.05.26 - 11:48
Pfizer receives EC approval for Hympavzi to treat haemophilia (PBR)
 
The approval covers adults and adolescents in the European Union (EU) who weigh at least 35kg and have haemophilia A (factor VIII deficiency) with factor VIII inhibitors, or The post Pfizer receives EC approval for Hympavzi to treat haemophilia appeared first on Pharmaceutical Business review....
14.05.26 - 00:15
Top Analyst Reports for Meta, Pfizer & Salesforce (Zacks)
 
Meta ramps up AI infrastructure and ad tools as Pfizer rebounds and Salesforce expands AI offerings amid macro pressures....
13.05.26 - 19:00
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029? (Zacks)
 
PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds....
13.05.26 - 13:51
Pfizer granted label expansion for hemophilia therapy Hympavzi in Europe (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.05.26 - 10:15
Pfizer-Aktie: Bleibt für Dividenden-Anleger attraktiv (Sharedeals)
 
Die Aktie von Pfizer hat in den vergangenen Monaten deutlich besser abgeschnitten als viele andere Werte aus dem Gesundheitssektor. Trotz anhaltender Skepsis gegenüber Pharmaunternehmen mehren sich die Hinweise darauf, dass die schwierigste Phase nach dem Ende des Corona-Booms überwunden sein könnte. Für Anleger von Pfizer waren die vergangenen Jahre alles andere als einfach. Während Technologieaktien […] The post Pfizer-Aktie: Bleibt für Dividenden-Anleger attraktiv first appeared on sharedeals.de....
12.05.26 - 20:48
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer (Benzinga)
 
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval. Importance Rank:  1 read more...
12.05.26 - 19:36
Prediction: Pfizer Will Beat the Market Over the Next 5 Years (Fool)
 
It's a great time to "buy low."...
12.05.26 - 14:06
Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu (AFX)
 
NEW YORK CITY (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture ......
12.05.26 - 13:42
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.05.26 - 13:00
Is Pfizer a Buy, Sell, or Hold in 2026? (Fool)
 
Can a push into oncology and next-generation therapies make up for Pfizer's post-Covid letdown?...
12.05.26 - 11:48
Pfizer′s Net Income Drops in Q1. Is Its Dividend Still Safe? (Fool)
 
At 6.7%, Pfizer's dividend yield is exceptionally high, but whether it's sustainable is debatable....
11.05.26 - 22:00
Is This a Sign Pfizer′s Aggressive Growth Strategy Is Paying Off? (Fool)
 
Pfizer's acquired and recently launched products generated strong growth last quarter....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Trinke Tee, und du kommst zu Kräften. - Sprichwort China
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!